Proteomics

Dataset Information

0

Co-expression analysis of label-free proteomics data reveals prognostic biomarkers in pancreatic ductal adenocarcinoma

ABSTRACT: Despite extensive biological and clinical studies, including comprehensive genomics and transcriptomics analysis, pancreatic ductal adenocarcinoma (PDAC) remains a devastating disease, with poor survival and no effective therapies to date. Correlation networks are emerging as a powerful approach to infer tumor biology and to prioritize candidate genes as biomarkers or drug targets. In this study we applied a weighted co-expression analysis to the functionally relevant proteome of 20 surgically resected patients with PDAC. We obtained twelve modules with overlapping yet distinct biology, which implicated metabolism and ECM complexes in several modules. Notably, one module enriched for metabolic processes and epithelial-mesenchymal-transition (EMT) was significantly associated with overall survival (p=0.01) and was validated in public RNA data (p=0.02). The prognostic value of three proteins (SPTBN1, KHSRP and PYGL) belonging to this module was confirmed using immunohistochemistry in a cohort of 82 radically resected patients.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Pancreatic Ductal Cell, Pancreatic Ductal Adenocarcinoma Cell

DISEASE(S): Pancreatic Ductal Carcinoma

SUBMITTER: Sander Piersma  

LAB HEAD: Connie Ramona Jimenez

PROVIDER: PXD015744 | Pride | 2020-09-01

REPOSITORIES: Pride

Json Xml
altmetric image

Publications

Co-expression analysis of pancreatic cancer proteome reveals biology and prognostic biomarkers.

Mantini G G   Vallés A M AM   Le Large T Y S TYS   Capula M M   Funel N N   Pham T V TV   Piersma S R SR   Kazemier G G   Bijlsma M F MF   Giovannetti E E   Jimenez C R CR  

Cellular oncology (Dordrecht) 20200829 6

<h4>Purpose</h4>Despite extensive biological and clinical studies, including comprehensive genomic and transcriptomic profiling efforts, pancreatic ductal adenocarcinoma (PDAC) remains a devastating disease, with a poor survival and limited therapeutic options. The goal of this study was to assess co-expressed PDAC proteins and their associations with biological pathways and clinical parameters.<h4>Methods</h4>Correlation network analysis is emerging as a powerful approach to infer tumor biology  ...[more]

Similar Datasets

Proteomics proteome landscapes of pancreatic cancer human-in-mouse patient-derived xenograft (PDX) models.
2021-09-09 | PXD017393 | Pride
Proteomics Combined expression of plasma CA19-9 and thrombospondin-2 for accurate diagnosis of pancreatic cancer and distal cholangiocarcinoma– A proteome approach
2020-05-26 | PXD012480 | Pride
Proteomics Stromal and epithelial proteome landscapes of pancreatic cancer predict poor prognosis and identify therapeutic options
2021-09-08 | PXD011289 | Pride
Proteomics Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma
2021-09-10 | PXD024548 | Pride
Proteomics Omics Analysis of Pancreatic Cancer Platelets Reveals Active “Education”, including Dysregulation of Splicing Signature and Inhibition of SPARC by Modified Forms of miRNAs
2021-09-09 | PXD022514 | Pride
Proteomics (Phospho-)proteomic analysis of gemcitabine resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment response
2019-06-19 | PXD010112 | Pride
Proteomics Proteomic analysis upon miR195/497 replacement reveals potential chemo sensitizing candidates for colorectal cancer
2019-09-27 | PXD015369 | Pride
Proteomics Lipopolysaccharide-regulated secretion of soluble and vesicle-based colorectal cancer cell proteins
2022-02-28 | PXD011611 | Pride
Proteomics Tumor heterogeneity underlies differential cisplatin sensitivity in mouse models of small cell lung cancer
2019-11-12 | PXD010680 | Pride
Proteomics,Multiomics Identification of differentially expressed splice variants by the proteogenomic pipeline SPLICIFY
2017-07-28 | PXD006486 | Pride